Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression

Endocrine-Related Cancer

Volumn 21, Issue 5, 2014, Pages 755-767

  Champa, Devora ^a   Russo, Marika A ^a   Liao, Xiao Hui ^b   Refetoff, Samuel ^b,c   Ghossein, Ronald A ^d   Di Cristofano, Antonio ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cell death; Mouse model; Thyroid cancer; University of Chicago

Indexed keywords

ANTINEOPLASTIC AGENT; BCL2-RELATED PROTEIN A1; MCL1 PROTEIN, MOUSE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; OBATOCLAX; PROTEIN BCL 2; PROTEIN MCL 1; PYRROLE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; THYROID NEOPLASMS; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAP KINASE KINASE KINASE 1; MAP KINASE KINASE KINASE 2; MICE, TRANSGENIC; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; RNA, MESSENGER; THYROID NEOPLASMS; TUMOR BURDEN;

EID: 84907532336     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0268     Document Type: Article

References (41)

1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 1167-1214. (doi:10.1089/thy.2009.0110)
2. Antico Arciuch VG, Dima M, Liao XH, Refetoff S & Di Cristofano A 2010 Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene 29 5678-5686. (doi:10.1038/onc.2010.308)
3. Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, Refetoff S, Montagna C & Di Cristofano A 2011 Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2 1109-1126.
4. Basit F, Cristofanon S & Fulda S 2013 Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death and Differentiation 20 1161-1173. (doi:10.1038/cdd.2013.45)
5. Branet F, Brousset P, Krajewski S, Schlaifer D, Selves J, Reed JC & Caron P 1996 Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. Journal of Clinical Endocrinology and Metabolism 81 2726-2730. (doi:10.1210/jcem.81.7.8675602)
6. Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF et al. 2014 Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology 8 544-554. (doi:10.1016/j.molonc.2014.01.003)
7. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N et al. 2011 Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. Journal of Clinical Investigation 121 4700-4711. (doi:10.1172/JCI46382)
8. Charles RP, Silva J, Iezza G, Phillips WA & McMahon M 2014 Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Molecular Cancer Research 12 979-986. (doi:10.1158/1541-7786.MCR-14-0158-T)
9. Chou TC & Talalay P 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22 27-55. (doi:10.1016/0065-2571(84)90007-4)
10. Ertel F, Nguyen M, Roulston A & Shore GC 2013 Programming cancer cells for high expression levels of Mcl1. EMBO Reports 14 328-336. (doi:10.1038/embor.2013.20)
11. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J & Tallini G 2003 ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 21 3226-3235. (doi:10.1200/JCO.2003.10.130)
12. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K et al. 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 6646-6656. (doi:10.1038/sj.onc.1208822)
13. Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R et al. 2013 BCL2A1 is a lineagespecific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. PNAS 110 4321-4326. (doi:10.1073/pnas.1205575110)
14. Heidari N, Hicks MA & Harada H 2010 GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death & Disease 1 e76. (doi:10.1038/cddis.2010.53)
15. Ibrahimpasic T, Ghossein RM, Carlson DL, Chernichenko N, Nixon I, Palmer FL, Lee NY, Shaha AR, Patel SG, Tuttle RM et al. 2013 Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan-Kettering Cancer Center experience. Thyroid 23 997-1002. (doi:10.1089/thy.2012.0403)
16. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S & Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 375-378. (doi:10.1210/endo.137.1.8536638)
17. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M & Berns A 2001 Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genetics 29 418-425. (doi:10.1038/ng747)
18. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 65 4238-4245. (doi:10.1158/0008-5472.CAN-05-0047)
19. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA & Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30 3153-3162. (doi:10.1038/onc.2011.44)
20. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L & Kimura S 2004 Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 39 212-216. (doi:10.1002/gene.20043)
21. McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM & Jacks T 2014 p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. PNAS 111 E1600-E1609. (doi:10.1073/pnas.1404357111)
22. Metais JY, Winkler T, Geyer JT, Calado RT, Aplan PD, Eckhaus MA & Dunbar CE 2012 BCL2A1a over-expression in murine hematopoietic stem and progenitor cells decreases apoptosis and results in hematopoietic transformation. PLoS ONE 7 e48267. (doi:10.1371/journal.pone.0048267)
23. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L, Billot X et al. 2007 Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. PNAS 104 19512-19517.(doi:10.1073/pnas.0709443104)
24. Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 15 319-327. (doi:10.1385/EP:15:4:319)
25. Pohlenz J, Maqueem A, Cua K, Weiss RE, Van Sande J & Refetoff S 1999 Improved radioimmunoassay for measurement of mouse thyrotropin in serum: strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid 9 1265-1271. (doi:10.1089/thy.1999.9.1265)
26. Pringle DR, Vasko VV, Yu L, Manchanda PK, Lee AA, Zhang X, Kirschner JM, Parlow AF, Saji M, Jarjoura D et al. 2014 Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. Journal of Clinical Endocrinology and Metabolism 99 E804-E812. (doi:10.1210/jc.2013-3101)
27. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P & Mesirov JP 2006 GenePattern 2.0. Nature Genetics 38 500-501. (doi:10.1038/ng0506-500)
28. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 69 4885-4893. (doi:10.1158/0008-5472.CAN-09-0727)
29. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH & DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 2155-2160. (doi:10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E)
30. Siegel R, Naishadham D & Jemal A 2013 Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63 11-30. (doi:10.3322/caac.21166)
31. Siironen P, Hagstrom J, Maenpaa HO, Louhimo J, Heikkila A, Heiskanen I, Arola J & Haglund C 2010 Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 79 400-408. (doi:10.1159/000322640)
32. Suzuki H, Willingham MC & Cheng SY 2002 Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12 963-969. (doi:10.1089/105072502320908295)
33. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P et al. 2008 ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research 68 3421-3428. (doi:10.1158/0008-5472.CAN-07-5836)
34. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM & Engelman JA 2012 MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Research 72 3228-3237. (doi:10.1158/0008-5472.CAN-11-3747)
35. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 375-387. (doi:10.1016/S1535-6108(04)00085-6)
36. Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD et al. 2013 Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 121 2689-2703. (doi:10.1182/blood-2012-04-425033)
37. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M et al. 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology 31 1256-1264. (doi:10.1097/PAS.0b013e3180309e6a)
38. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M & Nikiforov YE 2009 RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. Journal of Clinical Endocrinology and Metabolism 94 4735-4741. (doi:10.1210/jc.2009-1233)
39. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH & Singh B 2002 Genome-wide appraisal of thyroid cancer progression. American Journal of Pathology 161 1549-1556. (doi:10.1016/S0002-9440(10)64433-1)
40. Yoon YK, Kim HP, Han SW, Oh do Y, Im SA, Bang YJ & Kim TY 2010 KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Molecular Carcinogenesis 49 353-362. (doi:10.1002/mc.20607)
41. Yu L & Liu S 2013 Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics. Seminars in Cancer Biology 23 553-560. (doi:10.1016/j.semcancer.2013.08.008)